Pharmaceutical

Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

Chimeric Bait Receptor-programmed macrophages show promise for treatment of Non-Hodgkin LymphomaLONDON, UK / ACCESSWIRE / November 27, 2023 / Hemogenyx…

12 months ago

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,…

12 months ago

TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughsCHICAGO, Nov. 26, 2023 (GLOBE NEWSWIRE) --…

12 months ago

BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system

BBS-Bioactive Bone Substitutes Plc, press release, 25 November 2023 at 11.00 a.m. BBS-Bioactive Bone Substitutes Plc ("BBS") has received confirmation…

12 months ago

Positron Corporation Announces Attrius® PET System Sale

Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular…

12 months ago

Bionxt Solutions Announces Convertible Debenture and Interest Settlement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR…

12 months ago

New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder

TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

12 months ago

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

12 months ago

Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

12 months ago

iZafe Group and Atea Sweden Have Entered into an Agreement with VGR in the Field of Welfare Technology

STOCKHOLM, SE / ACCESSWIRE / November 23, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that the…

12 months ago